Pure Biologics is selling at 13.56 as of the 14th of December 2024; that is 9.12% down since the beginning of the trading day. The stock's lowest day price was 13.38. Pure Biologics has hardly any chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 15th of September 2024 and ending today, the 14th of December 2024. Click here to learn more.
Although Pure Biologics' alpha and beta are two of the key measurements used to evaluate Pure Biologics' performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pure Biologics stock to make a market-neutral strategy. Peer analysis of Pure Biologics could also be used in its relative valuation, which is a method of valuing Pure Biologics by comparing valuation metrics with similar companies.
When running Pure Biologics' price analysis, check to measure Pure Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pure Biologics is operating at the current time. Most of Pure Biologics' value examination focuses on studying past and present price action to predict the probability of Pure Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pure Biologics' price. Additionally, you may evaluate how the addition of Pure Biologics to your portfolios can decrease your overall portfolio volatility.